Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : BVX-0918A
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Biovaxys
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BVX-0918A, BioVaxys’s cancer vaccines are created by extracting a patient’s own cancer cells, chemically treating them with a hapten, and re-injecting them into the patient to induce an immune response to proteins which are otherwise not immunogenic.
Product Name : BVX-0918A
Product Type : Vaccine
Upfront Cash : Inapplicable
August 06, 2022
Lead Product(s) : BVX-0918A
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Biovaxys
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BVX-0918A
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Biovaxys
Deal Size : Undisclosed
Deal Type : Partnership
BioVaxys Cancer Vaccine Manufacturing Partner Bio Elpida Reaches Bioproduction Milestone
Details : Bio Elpida has completed the technology process transfer of BVX-0918A with BioVaxys and started the development phase using a Quality by Design (“QbD”) approach which includes establishing the control methods and manufacturing process development.
Product Name : BVX-0918A
Product Type : Vaccine
Upfront Cash : Undisclosed
September 17, 2021
Lead Product(s) : BVX-0918A
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Biovaxys
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : BVX-0918A
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Biovaxys
Deal Size : Undisclosed
Deal Type : Agreement
Details : BioVaxys has signed the definitive exclusive bioproduction agreement with BioElpida, to begin the clinical-grade bioproduction and aseptic packaging for BXV-0918A, BioVaxys’ vaccine candidate for Stage III/Stage IV ovarian cancer.
Product Name : BVX-0918A
Product Type : Vaccine
Upfront Cash : Undisclosed
March 05, 2021
Lead Product(s) : BVX-0918A
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Biovaxys
Deal Size : Undisclosed
Deal Type : Agreement